Processing...
Clinical Trials for Liver Cancer
Search
Search
There are 112 active trials for advanced/metastatic liver cancer.
Click on a trial to see more information.
112 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with advanced/metastatic solid tumors (ECOG 0–1) receive IV TORL-4-500 monotherapy every 3 weeks; TORL-4-500 is a DLK1-targeted antibody–drug conjugate (humanized anti-DLK1 IgG1 linked to MMAE via a val-cit linker) intended for DLK1-expressing tumors. Key exclusions include uncontrolled/symptomatic brain mets, significant cardiac disease, active infections, unresolved prior toxicities, and recent other malignancies.
ClinicalTrials.gov ID: NCT06005740
TrialFetch AI summary: Adults with advanced/metastatic HCC (Child-Pugh A–B7) after ≥1 prior systemic therapy and harboring a WNT-pathway–activating alteration receive ALN-BCAT, an IV siRNA that silences CTNNB1 (β-catenin) via hepatic LNP delivery, as monotherapy or combined with pembrolizumab. Excludes fibrolamellar/sarcomatoid/mixed cholangio-HCC and symptomatic extrahepatic disease; aims to define dose and assess preliminary activity, with the combo exploring β-catenin suppression to enhance PD-1 response.
ClinicalTrials.gov ID: NCT06600321
TrialFetch AI summary: Adults with unresectable/metastatic HCC (Child-Pugh A; BCLC B not LRT-eligible or C) or other advanced solid tumors harboring activating FGFR3/FGFR4 alterations or focal FGF19 amplification; prior FGFR inhibitors allowed in dose-escalation but excluded for FGFR4/pan-FGFR in HCC expansion. Patients receive oral TYRA-430, a reversible, FGFR4/FGFR3-biased tyrosine kinase inhibitor targeting FGF19/FGFR-driven tumors.
ClinicalTrials.gov ID: NCT06915753
TrialFetch AI summary: Adults with centrally confirmed GPC3-positive advanced or metastatic solid tumors—emphasizing HCC (BCLC B not eligible for LRT or C, Child-Pugh A, ECOG 0–1)—receive AZD9793 monotherapy given IV or SC after prior therapy (Part A: ≥1 prior line; Part B: ≤1 prior line). AZD9793 is an asymmetric trispecific T-cell engager targeting GPC3 and engaging the TCR and CD8 co-receptor to bias CD8+ activation; exclusions include prior GPC3-targeted therapy and significant autoimmune, cardiac/CNS disease, or active infections.
ClinicalTrials.gov ID: NCT06795022
TrialFetch AI summary: Adults with advanced solid tumors refractory to standard therapy (ECOG 0–1, measurable disease) receive a single intravenous infusion of IDOV-Immune (VM-002), a genetically engineered oncolytic vaccinia virus designed for tumor-selective replication and lysis with immune-stimulating transgenes to enhance antitumor immunity. Key exclusions include prior oncolytic virus therapy, recent vaccinia/smallpox vaccination, active autoimmune disease requiring systemic therapy, significant cardiopulmonary disease, uncontrolled infection, and unstable/untreated CNS metastases.
ClinicalTrials.gov ID: NCT06910657
TrialFetch AI summary: Adults with unresectable or metastatic hepatocellular carcinoma (ECOG 0–1, Child-Pugh A) receive ZW251, an investigational glypican‑3–targeted antibody–drug conjugate delivering a camptothecin-based topoisomerase I inhibitor. Single‑arm dose escalation and expansion assess safety, PK, and preliminary activity to determine a recommended dose.
ClinicalTrials.gov ID: NCT07164313
TrialFetch AI summary: Adults (≥18) with locally advanced or metastatic solid tumors that are refractory/intolerant to standard therapies or lack standard options (ECOG 0–2; no active CNS/leptomeningeal metastases) receive IV JMT108 every 2 weeks (with possible alternate schedules in expansion). JMT108 is a fully human anti–PD-1 antibody fused to IL-15 intended to combine checkpoint blockade with IL-15–driven activation/proliferation of CD8+ T cells and NK cells, with tumor-specific expansion cohorts including lung, colorectal, hepatocellular, gastric cancers, melanoma, and other solid tumors.
ClinicalTrials.gov ID: NCT07317505
TrialFetch AI summary: Enrolls adults with metastatic or locally advanced unresectable solid tumors (ECOG ≤2; measurable/evaluable by RECIST) with biologic rationale for RBM39 degradation; adolescents ≥16 may enroll for Ewing sarcoma or other supported malignancies, and stable treated brain metastases are allowed. Patients receive oral ST-01156, a small-molecule molecular glue RBM39 degrader (RNA-binding/splicing factor), dosed once daily on a 5-days-on/2-days-off schedule in 28-day cycles with dose escalation to define MTD/RP2D and assess early antitumor activity.
ClinicalTrials.gov ID: NCT07197554
TrialFetch AI summary: Adults with RECIST-measurable advanced solid tumors (excluding primary CNS malignancies), ECOG 0–1, adequate organ function, and controlled/treated CNS disease (if present) after standard therapies are eligible. Patients receive PLT012 IV every 3 weeks, a first-in-class humanized anti-CD36 IgG4 “metabolic checkpoint” monoclonal antibody intended to block CD36-mediated lipid uptake and restore antitumor T-cell function, with treatment continuing until progression or unacceptable toxicity.
ClinicalTrials.gov ID: NCT07337525
TrialFetch AI summary: For patients <30 years with unresectable, relapsed/refractory solid tumors requiring accessible biopsy (Part 2 enriched for fibrolamellar carcinoma; also HCC, DSRCT, and non-CNS malignant rhabdoid tumor), this single-arm study evaluates a 21-day regimen of metronomic oral cyclophosphamide plus PK-guided oral sorafenib (multikinase inhibitor of RAF/VEGFR/PDGFR) with IV bevacizumab (anti–VEGF-A) and IV atezolizumab (anti–PD-L1 checkpoint inhibitor) every 21 days. The trial focuses on safety/RP2D and preliminary response with sorafenib exposure targeting to reduce variability/toxicity.
ClinicalTrials.gov ID: NCT05468359